Completed

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

J1O-MC-JZHC - ClinicalTrials.gov - NCT03955939

The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.
How long will I be in the trial?
Your participation in this trial could last up to 23 months, depending on your cancer type and how you and your tumor respond.
Email
Completed

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

J1O-MC-JZHC - ClinicalTrials.gov - NCT03955939

The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.
How long will I be in the trial?
Your participation in this trial could last up to 23 months, depending on your cancer type and how you and your tumor respond.
Email

Key Requirements

Age :

18+

Sex:

Female

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

Female

Participants must

Participants must have hormone receptor positive and HER2 negative metastatic breast cancer

Participants must have progressed on at least 1 line of endocrine therapy and 1 cyclin dependent kinase (CDK)4/6 inhibitor

Participants must be able and willing to undergo mandatory tumor biopsy

Participants must have normal organ function

Participants must be able to swallow capsules

Participants must NOT

Participants must not have had prior chemotherapy for metastatic breast cancer. Chemotherapy in the adjuvant/neoadjuvant setting is permitted

Participants must not be currently enrolled in a clinical study

Participants must not have another serious medical condition

Participants must not have previously received an aurora kinase inhibitor

Trial Summary

Conditions the trial is for

Metastatic Breast Cancer

What the trial is testing?

LY3295668 Erbumine, Endocrine therapy, Midazolam

Could I receive a Placebo?

no

Enrollment Goal

100

Trial Dates

August 2019 - May 2020

Trial Phase

1

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

Female

Participants must

Participants must have hormone receptor positive and HER2 negative metastatic breast cancer

Participants must have progressed on at least 1 line of endocrine therapy and 1 cyclin dependent kinase (CDK)4/6 inhibitor

Participants must be able and willing to undergo mandatory tumor biopsy

Participants must have normal organ function

Participants must be able to swallow capsules

Participants must NOT

Participants must not have had prior chemotherapy for metastatic breast cancer. Chemotherapy in the adjuvant/neoadjuvant setting is permitted

Participants must not be currently enrolled in a clinical study

Participants must not have another serious medical condition

Participants must not have previously received an aurora kinase inhibitor

Trial Summary

Conditions the trial is for

Metastatic Breast Cancer

What the trial is testing?

LY3295668 Erbumine, Endocrine therapy, Midazolam

Could I receive a Placebo?

no

Enrollment Goal

100

Trial Dates

August 2019 - May 2020

Trial Phase

1

Not the right fit? Sign up to receive updates on new Metastatic Breast Cancer trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Metastatic Breast Cancer Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?